Conceived over 30 years ago,1 CAR technology was transformed from academic curiosity into groundbreaking cancer therapy with the demonstration that T cell receptor (TCR) and co-stimulatory signaling could be efficiently delivered via a single CD28+CD3ζ (28ζ) or 41BB+CD3ζ (BBζ) fusion.2 Here, CD247 is linked to cancer.